Synthesis method and application of axially chiral N-aryl benzimidazole analogue
By introducing chiral phosphoric acid catalysis in benzimidazole synthesis, axial chiral N-aryl benzimidazole analogs were constructed, which solved the problem of chiral and aromatic ring deletion in traditional synthesis methods, and achieved the HBV virus Effective inhibition of the disease demonstrates its antiviral activity.
Patent Information
- Application Number
- CN202411023875.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-29
AI Technical Summary
Traditional benzimidazole synthesis methods fail to introduce chiral and aromatic rings, limiting their biological activity and drug-effective potential.
The introduction of aromatic rings was achieved by the reaction of N-(aryl)benzene-1,2-diamine with aromatic aldehyde, using chiral phosphoric acid catalyst to construct axial chiral N-arylbenzimidazole analogue under mild conditions. and chiral synthesis.
The resulting axial chiral N-arylbenzimidazole analogues showed strong physiological activity against HBV virus HepG2/2.15 cells and had potential antiviral effects.
Smart Images

Figure CN118955397A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of organic chemistry, and specifically relates to a method for synthesizing axial chiral N-aryl benzimidazole analogs by catalysis of chiral phosphoric acid and application thereof. Background Art
[0002] Imidazole benzo derivatives are called benzimidazoles, also known as 1H-benzimidazole and 1,3-benzodiazole. They are composed of a benzene ring fused with a five-membered imidazole ring and are an important heterocyclic pharmacophore.
[0003] Benzimidazoles are also important building blocks of many biologically active heterocyclic compounds, which have attracted widespread attention due to their diverse biological and clinical applications. In addition, benzimidazole derivatives are structural isomers of naturally occurring nucleotides, which allows them to easily interact with biopolymers of living systems, arousing the interest of researchers, who have synthesized various benzimidazole derivatives and screened their various biological activities, namely anticancer, antibacterial, antiviral, anti-inflammatory, analgesic, anti-ulcer, antioxidant, etc.
[0004] Among many axial chiral compounds, benzimidazoles have very broad biological activities due to their special structure and exist in many biologically active molecules. They can be used as intermediates for certain drugs and are widely used in the research of medicines and pesticides.
[0005] The introduction of aromatic functional groups at positions 1 and 2 in the parent molecule significantly affects its chemical, physical and biological properties. Many molecules containing aromatic rings are known to have important application values. Many drug molecules contain aromatic groups. The traditional synthesis of benzimidazole uses o-phenylenediamine and formic acid to form a cyclization, and does not introduce the concept of chirality.
[0006] In view of the above shortcomings of the prior art, the present invention introduces the concept of chirality into the synthesis of benzimidazole, and also realizes the first introduction of an aromatic ring into benzimidazole, ultimately generating an N-aryl benzimidazole analogue with axial chirality containing an aromatic ring at the 2-position. Summary of the invention
[0007] In order to overcome the above technical defects, the purpose of the present invention is to provide an axially chiral N-arylbenzimidazole analogue, and study its synthesis method and compound application. Through the reaction of N-(aryl)benzene-1,2-diamine with aromatic aldehyde, axially chiral benzimidazole is selectively constructed with chiral phosphoric acid to obtain an axially chiral N-arylbenzimidazole analogue containing biological activity. The method of the present invention does not require transition metals or stoichiometric oxidants, the reaction raw materials are easily available, the synthesis steps are simple, and the reaction conditions are mild. These axially chiral N-arylbenzimidazole analogues show strong physiological activity against HepG2 / 2.2.15 cells that can continuously and stably express HBV virus, and can be further used in potential antiviral substances.
[0008] The axially chiral N-arylbenzimidazole analogs of the present invention, including racemates and enantiopure compounds thereof, have the following general structural formula:
[0009]
[0010] Wherein: R is selected from phenyl, substituted phenyl, furyl; wherein the substituent in the substituted phenyl is C1-C4 alkyl, halogen, trifluoromethyl; R 1 ,R 2 Each is independently selected from C1-C4 alkyl, halogen, and trifluoromethyl.
[0011] The present invention also provides a method for synthesizing the above-mentioned axial chiral N-aryl benzimidazole analogs, comprising the following steps: using N-(aryl)benzene-1,2-diamine 1 and aromatic aldehyde 2 as raw materials, reacting in an organic solvent in the presence of a chiral phosphoric acid catalyst CPA to obtain an axial chiral N-aryl benzimidazole analog 3. The reaction equation is as follows:
[0012]
[0013] Wherein: R is selected from phenyl, substituted phenyl, furyl; wherein the substituent in the substituted phenyl is C1-C4 alkyl, halogen, trifluoromethyl; R 1 ,R 2 Each is independently selected from C1-C4 alkyl, halogen, and trifluoromethyl.
[0014] Furthermore, in the above technical solution, the molar ratio of the N-(aryl)benzene-1,2-diamine 1, aromatic aldehyde 2 and chiral phosphoric acid CPA is 1:1-2:0.05-0.10.
[0015] Furthermore, in the above technical solution, the reaction is carried out in an ethyl acetate solvent in the presence of sodium sulfate.
[0016] Furthermore, in the above technical solution, the reaction is carried out under the protection of an inert gas.
[0017] Furthermore, in the above technical solution, the organic solvent is selected from ethyl acetate; and the reaction temperature is selected from 0-30°C.
[0018] Furthermore, in the present technical solution, by changing the substituents of substrates 1 and 2, axially chiral N-arylbenzimidazoles containing different substituents can be obtained; the representative structures are as follows:
[0019]
[0020] The present invention also provides the use of the aforementioned axial chiral N-aryl benzimidazole analogs in the preparation of antiviral drugs.
[0021] Furthermore, in the above technical solution, the antiviral agent is selected from HepG2 / 2.2.15 cells which can stably and sustainably express HBV virus.
[0022] Advantageous Effects of the Invention
[0023] 1. The present invention uses N-(naphthalene-1-yl)benzene-1,2-diamine and aromatic aldehyde as raw materials and chiral phosphoric acid as a catalyst to selectively construct axial chiral benzimidazole analogs, introduces the concept of chirality into the synthesis of benzimidazole, and is also the first time to introduce an aromatic ring into benzimidazole, ultimately generating an N-aryl benzimidazole analog with axial chirality containing an aromatic ring at the 2-position.
[0024] 2. The N-arylbenzimidazole analogs of the present invention exhibit strong cell activity against HepG2 / 2.2.15 cells that can stably and continuously express HBV virus. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 The experimental steps for the biological activity test of axially chiral N-arylbenzimidazole analogs in the examples;
[0026] Figure 2 The relative expression of HBV DNA in HepG2 / 2.2.15 cells by axial chiral N-arylbenzimidazole analogs in the examples;
[0027] Figure 3 The expression amount of HBsAg in HepG2 / 2.2.15 cells by axial chiral N-arylbenzimidazole analogs in the examples;
[0028] Figure 4 The expression level of HBeAg in HepG2 / 2.2.15 cells by the axially chiral N-arylbenzimidazole analogs in the examples. Specific embodiments
[0029] The present invention will be further described below by specific examples. These embodiments should be understood to be only used to illustrate the present invention and not to limit the scope of protection of the present invention. After reading the content of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent changes and modifications also fall within the scope defined by the claims of the present invention.
[0030] In this reaction, N-(aryl)benzene-1,2-diamine 1a and benzaldehyde 2a were used as template substrates to optimize the reaction conditions. The configuration of the chiral phosphoric acid catalyst, solvent, water absorbent, temperature, and molar ratio of the two substrates were optimized, and the optimal reaction conditions were finally obtained. Under these optimal conditions, the substrate range of aromatic aldehyde 2 was expanded, and six axially chiral N-arylbenzimidazole analogs with good activity were finally obtained.
[0031] Example 1
[0032] General experimental operation steps: Under argon atmosphere, take a 10mL Schlenk tube equipped with a stirring bar, add 100mg of sodium sulfate, and flame dry under high vacuum. After the reaction tube and sodium sulfate are cooled to room temperature, ventilate and put the reaction tube into a glove box. N-(aryl)benzene-1,2-diamine 1 (0.10mmol) and chiral phosphoric acid CPA (0.01mmol, 10mol%) are dissolved in 1mL of ultra-dry ethyl acetate, stirred at 5℃ for 10 minutes, and finally aromatic aldehyde 2 (0.20mmol) is added. After TLC (thin layer chromatography) monitoring, the reaction mixture is directly purified by flash column chromatography to obtain axial chiral N-arylbenzimidazole analog 3.
[0033]
[0034] 2-(3-bromophenyl)-1-(naphthalen-1-yl)-1H-benzo[d]imidazole (29.1 mg); yield 53%; 1 H NMR (600MHz, CDCl3) δ8.05(d,J=8.4Hz,1H),8.01(d,J=8.4Hz,1H),7.96(d,J=8.4Hz,1H),7.92(t,J=1.8Hz,1H),7.59 -7.55(m,2H),7.45-7.40(m,2H),7.39-7.34(m,3H),7.23-7.19(m,2H),6.95(t,J=7.8Hz,1H),6.89(d,J=7.8Hz,1H); 1313C NMR (150 MHz, CDCl3) δ 151.7, 142.9, 138.4, 134.6, 133.3, 132.6, 132.1, 132.0, 130.3, 130.1, 129.8, 128.8, 128.0, 127.3, 127.0, 126.7, 125.8, 123.9, 123.4, 122.7, 122.6, 120.2, 111.2; HRMS (ESI) m / z: [M+H] + Calcd for C23H16N2Br 399.0491; Found 399.0491.
[0035]
[0036] 1-(naphthalen-1-yl)-2-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazole (31.8 mg); Yield 62%; 1 1H NMR (400 MHz, CDCl3) δ 8.07 - 7.96 (m, 3H), 7.67 - 7.54 (m, 4H), 7.44 - 7.38 (m, 6H), 7.24 - 7.19 (m, 1H), 6.89 (d, J = 8.0 Hz, 1H); 13 13C NMR (100 MHz, CDCl3) δ 151.7, 143.0, 138.5, 134.7, 133.5, 133.3, 131.4, 131.1, 130.3, 130.2, 129.1, 128.8, 128.1, 127.4, 126.7, 125.9, 125.4 (q, J = 4.0 Hz), 125.3, 124.1, 123.5, 122.7, 122.6, 120.3, 111.3; 19 19F NMR (564 MHz, CDCl3) δ –63.0; HRMS (ESI) m / z: [M+H] + Calcd for C24H16N2F3 389.1260; Found 389.1252.
[0037] 1-(naphthalene-1-yl)-2-phenyl-1H-benzo[d]imidazole (25.6 mg); Yield 60%; 11H NMR (400 MHz, CDCl3) δ 8.02 - 7.94 (m, 3H), 7.58 - 7.50 (m, 4H), 7.41 (d, J = 3.6 Hz, 2H), 7.39 - 7.34 (m, 2H), 7.26 - 7.22 (m, 1H), 7.20 - 7.14 (m, 3H), 6.86 (d, J = 8.1 Hz, 1H); 13 13C NMR (100 MHz, CDCl3) δ 153.5, 143.0, 138.3, 134.6, 133.7, 130.4, 130.0, 129.8, 129.6, 128.9, 128.7, 128.4, 127.8, 127.2, 126.7, 125.8, 123.5, 123.2, 123.0, 120.0, 111.1; HRMS (ESI) m / z: [M + H] + Calcd for C23H17N2 321.1386; Found 321.1385.
[0038]
[0039] 2-(2-chlorophenyl)-1-(naphthalen-1-yl)-1H-benzo[d]imidazole (22.0 mg); Yield 42%; 1 1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 8.8 Hz, 2H), 7.54 - 7.49 (m, 1H), 7.47 - 7.28 (m, 7H), 7.24 - 7.17 (m, 2H), 7.09 - 7.04 (m, 1H), 6.95 (d, J = 8.1 Hz, 1H); 13 13C NMR (100 MHz, CDCl3) δ 151.6, 142.8, 137.1, 134.6, 134.5, 134.4, 132.1, 130.9, 130.1, 130.06, 129.9, 129.7, 128.5, 127.4, 126.9, 126.4, 126.36, 125.4, 123.8, 123.3, 123.1, 120.4, 111.3; HRMS (ESI) m / z: [M + H] + Calcd for C23H16N2Cl 355.0997; Found 355.0993.
[0040] 1-(naphthalen-1-yl)-2-(p-tolyl)-1H-benzo[d]imidazole (26.8 mg); yield 60%; 1 H NMR (600 MHz, CDCl3) δ 7.99 (dd, J = 12.0, 7.8 Hz, 2H), 7.94 (d, J = 7.8 Hz, 1H), 7.56 - 7.50 (m, 2H), 7.42 - 7.39 (m, 4H), 7.38 - 7.35 (m, 1H), 7.35 - 7.31 (m, 1H), 7.17 - 7.13 (m, 1H), 6.96 (d, J = 8.4 Hz, 2H), 6.83 (d, J = 7.8 Hz, 1H), 2.23 (s, 3H); 13 C NMR (150 MHz, CDCl3) δ 153.6, 143.1, 139.7, 138.4, 134.6, 133.8, 130.4, 129.7, 129.1, 128.8, 128.6, 127.8, 127.1, 126.7, 125.8, 123.3, 123.0, 119.8, 111.0, 21.4; HRMS (ESI) m / z: [M+H] + Calcd for C24H19N2 335.1543; Found 335.1539.
[0041]
[0042] 2-(furan-3-yl)-1-(naphthalen-1-yl)-1H-benzo[d]imidazole (25.1 mg); yield 61%; 1 H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 8.4 Hz, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.65 (t, J = 7.2 Hz, 1H), 7.58 - 7.54 (m, 2H), 7.41 - 7.30 (m, 2H), 7.26 - 7.14 (m, 3H), 6.90 - 6.85 (m, 2H), 6.66 (d, J = 1.2 Hz, 1H); 13 C NMR (100 MHz, CDCl3) δ 147.6, 143.1, 143.06, 142.3, 138.0, 134.7, 132.9, 130.6, 130.5, 128.6, 127.4, 126.8, 125.9, 123.4, 123.0, 122.7, 119.5, 116.9, 110.4, 110.0; HRMS (ESI) m / z: [M+H]+ Calcd for C21H15N2O311.1179; Found 311.1177
[0043] Example 2
[0044] This example is the detection process and results of the inhibition of HBV virus replication in cells by the compounds described in Example 1. The materials and consumables listed in this example can be obtained from commercial channels unless otherwise specified, and the cells and viruses are from the cell and microbial resource library of CTCC or other relevant institutions. The experimental method of this example is a standard molecular biology, cell biology or virology operation procedure, which can be easily understood and operated by researchers in the field.
[0045] The specific steps are as follows:
[0046] 1. Cells:
[0047] HepG2 / 2.2.15 (HBV ayw inserted, D subtype, 3182 bp, stable expression), culture conditions: DMEM+10% FBS+1% (strep++pen+)+380 μg / ml G418+0.2% L-Glutamine+0.2% non-essential amino acids.
[0048] Note: HBV DNA is carried by these cells as chromosomally integrated sequences and episomally as relaxed circular, covalently closed, and incomplete copies of the HBV genome. The majority of HBV DNA appears to be present in the form of covalently closed circular (ccc) and nicked recircularized forms, as well as incomplete copies of the genome.
[0049] 2. Main reagents:
[0050] DMEM (Gibco, cat:C11995500BT);
[0051] Fetal bovine serum FBS (Gibco, cat: 10270-106);
[0052] Double Pen-Strep (10,000U / mL) (M&C gene biotechnology, cat: G2723M3);
[0053] Anti-HBV positive drugs: 3TC (lamivudine; gift from Academician Chang Junbiao);
[0054] Tguide Smart Universal Genomic DNA Extraction Kit (TIANGEN, mat: 4995051)
[0055] Hepatitis B virus surface antigen (HBsAg) diagnostic kit (enzyme-linked immunosorbent assay) (KHB) Hepatitis B virus e antigen (HBeAg) detection kit (enzyme-linked immunosorbent assay) (KHB)
[0056] 3. Experimental steps: ( Figure 1 )
[0057] Step 1: Preliminary screening of compounds for inhibition of HBV activity:
[0058] The experiment set up two control groups, namely: ① positive drug group: add the final concentration of 50
[0059] μM 3TC; ② Virus control group: only DMSO was added without compound.
[0060] Step 2, HepG2 / 2.2.15 cells, 1x 105 cells / well, 12-well plate, 750 μL / well.
[0061] Step 3: 12-16 h after the cells are completely attached, add 750 μL DMEM and 1.5 μL of the compound to be tested (5 mM), and the final concentration of the compound is 5 μM.
[0062] Step 4: On the 4th day of culturing at 37°C, supplement with 250 μL of culture medium containing 5 μM of the compound to be tested.
[0063] Step 5: On the sixth day of culturing at 37°C, supplement with 250 μL of culture medium containing 5 μM of the compound to be tested.
[0064] Step 6: On the 8th day of culturing at 37°C, collect the cells and culture supernatant.
[0065] Step 7: Extract the sample DNA using an automatic nucleic acid extractor, and determine the inhibition rate of the compound on HBV virus using the qPCR method (real-time fluorescence quantitative polymerase chain reaction).
[0066] Step 8: Detect the expression levels of HBsAg and HBeAg using the HBsAg and HBeAg detection kits and the ELASA method (enzyme-linked immunosorbent assay).
[0067] Supplement: qPCR detection:
[0068] Primer: F Primer: 5'-CCTAGTAGTCAGTTATGTCAAC-3'
[0069] R Primer:5'-TCTATAAGCTGGAGGAGTGCGA-3'
[0070] Amplified gene: C gene
[0071] Amplification conditions: 95°C, 10 min;
[0072] 95℃, 15s; 60℃, 30s; 72℃, 30s×40
[0073] 4. Test results:
[0074] Initial screening of anti-HBV activity at a single concentration (5 μM) Figure 2-4 )
[0075] (Compound concentration: 5 μM)
[0076] (Control drug 3TC concentration: 50μM)
[0077] in conclusion:
[0078] 1. At a concentration of 5 μM, the differences in HBV DNA expression between the three compounds 3a, 3c, and 3f and the DMSO control group were extremely significant. Among them, the relative expression of HBV DNA in 3f reached 9.3%, and the effect of inhibiting DNA replication was extremely significant. Figure 2 )
[0079] 2. At a concentration of 5 μM, the six compounds had no significant inhibitory effect on the expression of HBsAg. Figure 3 )
[0080] 3. At a concentration of 5 μM, the six compounds had no significant inhibitory effect on the expression of HBeAg. Figure 4 )
[0081] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. Axially chiral N-aryl benzimidazole analogs, including racemates and enantiomerically pure compounds thereof, having the following general structural formula: in: R is selected from phenyl, substituted phenyl, furyl; wherein the substituent in the substituted phenyl is C1-C4 alkyl, halogen, trifluoromethyl; R 1 ,R 2 Each is independently selected from C1-C4 alkyl, halogen, and trifluoromethyl.
2. The method for synthesizing the axially chiral N-arylbenzimidazole analogue according to claim 1, characterized in that: The method comprises the following steps: using N-(aryl)benzene-1,2-diamine 1 and aromatic aldehyde 2 as raw materials, reacting in an organic solvent in the presence of a chiral phosphoric acid catalyst CPA to obtain an axially chiral N-aryl benzimidazole analogue 3; Wherein: R is selected from phenyl, substituted phenyl, furyl; wherein the substituent in the substituted phenyl is C1-C4 alkyl, halogen, trifluoromethyl; R 1 ,R 2 Each is independently selected from C1-C4 alkyl, halogen, and trifluoromethyl.
3. The method for synthesizing the axially chiral N-arylbenzimidazole analogue according to claim 2, characterized in that: The molar ratio of N-(aryl)benzene-1,2-diamine 1, aromatic aldehyde 2 and chiral phosphoric acid CPA is 1:1-2:0.05-0.
10.
4. The method for synthesizing the axially chiral N-arylbenzimidazole analogue according to claim 2, characterized in that: The organic solvent is selected from ethyl acetate; and the reaction temperature is selected from 0-30°C.
5. The method for synthesizing the axially chiral N-arylbenzimidazole analogue according to claim 2, characterized in that: The reaction was carried out under inert gas protection.
6. Use of the axially chiral N-arylbenzimidazole analogue as claimed in claim 1 in the preparation of antiviral drugs.
7. The use of the axially chiral N-aryl benzimidazole analogue according to claim 6 in the preparation of antiviral drugs, characterized in that: The antiviral agent is selected from HepG2 / 2.2.15 cells which can stably and continuously express the HBV virus.
Citation Information
Patent Citations
Preparation method for 2-(alpha-hydroxyl aryl) benzimidazole compound
CN109942496A
Nitrogen-nitrogen benzimidazole axial chiral compound as well as preparation method and application thereof
CN117402148A
Specific substrates and products of HSD17b13 as markers of liver disease and biomarkers for liver disease treatment
WO2022098757A1
